GlassScriptPhysician profile
Humaira Abid
NPI 1326356973
$815.94
in general payments reported to CMS, 2019-2025
19 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.72 · 2022: $29.80 · 2023: $126 · 2024: $312 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.80 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $151.77 | 2023-2025 | |
| Exact Sciences Corporation | $103.34 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $97.79 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $85.67 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $63.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $47.30 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $38.13 | 2024 | |
| Sanofi-Aventis U.S. LLC | $35.43 | 2023-2025 | |
| Amgen INC. | $30.94 | 2025 | Otezla, Repatha |
| Ultragenyx Pharmaceutical INC. | $26.20 | 2024 | Crysvita |
| Dexcom, INC. | $20.13 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $17.49 | 2024 | Veozah |
| Viiv Healthcare Company | $17.05 | 2023 | Apretude |
| Janssen Pharmaceuticals, INC | $14.93 | 2022 | |
| Dynavax Technologies Corporation | $14.72 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $14.16 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $14.00 | 2025 | Gardasil 9, Capvaxive, Enflonsia |
| Biogen, INC. | $13.66 | 2025 | Zurzuvae |
| Phathom Pharmaceuticals, INC. | $10.00 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humaira Abid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.